Quantcast
Featuring Demian Dressler, DVM and Susan Ettinger, DVM, Dip. ACVIM (Oncology), authors of The Dog Cancer Survival Guide

Curcumin

Updated: June 28th, 2018

There were many studies, articles and books Dr. Dressler and Dr. Ettinger used when writing The Dog Cancer Survival Guide. Here is a list of the most important references about the use of curcumin.

Please note that in vivo and clinical use citations were included whenever possible. We have also included links to the papers, where available. Most of the papers are found on the National Institute of Health’s online library, PubMed.

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Chirnomas D, et al. Mol Cancer Ther. 2006 Apr;5(4):952-61.

Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Kamat AM, Sethi G, Aggarwal BB. Mol Cancer Ther. 2007 Mar;6(3):1022-30.

Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Kunnumakkara AB, et al. Cancer Res. 2007 Apr 15;67(8):3853-61.

Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. Cabrespine-Faugeras A, et al. Nutr Cancer. 2010;62(2):148-53.

Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Kunnumakkara AB, et al. Int J Cancer. 2009 Nov 1;125(9):2187-97.

Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Kamat AM, Sethi G, Aggarwal BB. Mol Cancer Ther. 2007 Mar;6(3):1022-30.

Curcumin prevents adriamycin nephrotoxicity in rats. Venkatesan N,Punithavathi D, Arumugam V, Br J Pharmacol. 2000 January; 129(2): 231–234.

Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. Limtrakul P, Anuchapreeda S, Buddhasukh D. BMC Cancer. 2004 Apr 17;4:13.

Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Javvadi P, et al. Cancer Res. 2010 Mar 1;70(5):1941-50.

Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Chendil D, et al. Oncogene. 2004 Feb 26;23(8):1599-607.

The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Javvadi P, et al. Mol Pharmacol. 2008 May;73(5):1491-501.

Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Kunnumakkara AB, et al. Clin Cancer Res. 2008 Apr 1;14(7):2128-36.

Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines. Okunieff P, et al. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):890-8.

Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Sharma RA, et al. Clin Cancer Res. 2004 Oct 15;10(20):6847-54.

Phase II trial of curcumin in patients with advanced pancreatic cancer. Dhillon N, et al. Clin Cancer Res. 2008 Jul 15;14(14):4491-9.

Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo. Schaaf C, et al. Endocr Relat Cancer. 2009 Dec;16(4):1339-50.

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Lin YG, et al. Clin Cancer Res. 2007 Jun 1;13(11):3423-30.

Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Dorai T, et al. Prostate. 2001 Jun 1;47(4):293-303.

Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. Gururajan M, et al. J Immunol. 2007 Jan 1;178(1):111-21.

Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Shankar S, et al. Mol Cancer. 2008 Jan 29;7:16.

Curcumin: the story so far. Sharma RA, Gescher AJ, Steward WP. Eur J Cancer. 2005 Sep;41(13):1955-68.

Bioavailability of curcumin: problems and promises. Anand P, et al. Mol Pharm. 2007 Nov-Dec;4(6):807-18.

Induction of apoptosis by curcumin and its implications for cancer therapy. Karunagaran D, Rashmi R, Kumar TR. Curr Cancer Drug Targets. 2005 Mar;5(2):117-29.

Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Reuter S, et al. Biochem Pharmacol. 2008 Dec 1;76(11):1340-51.

Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Siwak DR, et al. Cancer. 2005 Aug 15;104(4):879-90.

Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Lev-Ari S, et al. Rheumatology (Oxford). 2006 Feb;45(2):171-7.

Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Lev-Ari S, et al. Clin Cancer Res. 2005 Sep 15;11(18):6738-44.

Discover the Full Spectrum Approach to Dog Cancer